Aminoglycosides in the intensive care unit: an old drug in a dynamic environment.
Aminoglycosides have historically been the mainstay of antibiotic therapy in the ICU. Despite the availability of numerous less toxic antibiotics, the clinical and microbiologic attributes of these agents have ensured their continued use in the management of infections in the critically ill patient. Innovative dosing regimens may replace traditional dosing methods if they are shown to provide improved clinical response with less toxicity potential.
Miyagawa
C I
CI
Department of Pharmacy, University of Cincinnati College of Medicine, OH 45267-0740.
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016638:Critical Illness; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D004352:Drug Resistance, Microbial; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007362:Intensive Care Units; D013997:Time Factors; D016896:Treatment Outcome
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents